These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 7531846

  • 1. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression.
    Cohen SM, Werrmann JG, Rasmusson GH, Tanaka WK, Malatesta PF, Prahalada S, Jacobs JG, Harris G, Nett TM.
    Prostate; 1995 Feb; 26(2):55-71. PubMed ID: 7531846
    [Abstract] [Full Text] [Related]

  • 2. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK, Ross M, Tate R, Chisholm GD.
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [Abstract] [Full Text] [Related]

  • 3. Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors.
    Laroque PA, Prahalada S, Molon-Noblot S, Cohen SM, Soper K, Duprat P, Peter CP, van Zwieten MJ.
    Prostate; 1995 Sep; 27(3):121-8. PubMed ID: 7567690
    [Abstract] [Full Text] [Related]

  • 4. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
    Zhao XF, Yang Y, Wang W, Qiu Z, Zhang P, Wang B.
    Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
    [Abstract] [Full Text] [Related]

  • 5. Magnetic resonance imaging of the efficacy of specific inhibition of 5 alpha-reductase in canine spontaneous benign prostatic hyperplasia.
    Cohen SM, Taber KH, Malatesta PF, Shpungin J, Berman C, Carlin JR, Werrmann JG, Prahalada S, Bryan RN, Cordes EH.
    Magn Reson Med; 1991 Sep; 21(1):55-70. PubMed ID: 1719333
    [Abstract] [Full Text] [Related]

  • 6. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride.
    Geller J, Sionit L.
    J Cell Biochem Suppl; 1992 Sep; 16H():109-12. PubMed ID: 1283893
    [Abstract] [Full Text] [Related]

  • 7. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G, Rittmaster RS, Klocker H.
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [Abstract] [Full Text] [Related]

  • 8. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G, Rittmaster RS, Klocker H.
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [Abstract] [Full Text] [Related]

  • 9. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
    Geller J.
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
    [Abstract] [Full Text] [Related]

  • 10. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
    Schwartz JI, Tanaka WK, Wang DZ, Ebel DL, Geissler LA, Dallob A, Hafkin B, Gertz BJ.
    J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
    [Abstract] [Full Text] [Related]

  • 11. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G, Rittmaster RS, Klocker H.
    Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
    [Abstract] [Full Text] [Related]

  • 12. Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride.
    Golchin-Rad K, Mogheiseh A, Nazifi S, Ahrari Khafi MS, Derakhshandeh N, Abbaszadeh-Hasiri M.
    Top Companion Anim Med; 2020 Mar; 38():100405. PubMed ID: 32115076
    [Abstract] [Full Text] [Related]

  • 13. Dihydrotestosterone concentration of beagle prostatic tissue: effect of age and hyperplasia.
    Ewing LL, Berry SJ, Higginbottom EG.
    Endocrinology; 1983 Dec; 113(6):2004-9. PubMed ID: 6196180
    [Abstract] [Full Text] [Related]

  • 14. CGP 53153: a new potent inhibitor of 5alpha-reductase.
    Häusler A, Allegrini PR, Biollaz M, Batzl C, Scheidegger E, Bhatnagar AS.
    J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
    [Abstract] [Full Text] [Related]

  • 15. Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response.
    Lamb JC, English H, Levandoski PL, Rhodes GR, Johnson RK, Isaacs JT.
    Endocrinology; 1992 Feb; 130(2):685-94. PubMed ID: 1733716
    [Abstract] [Full Text] [Related]

  • 16. Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat.
    di Salle E, Giudici D, Briatico G, Ornati G, Panzeri A.
    J Steroid Biochem Mol Biol; 1993 Nov; 46(5):549-55. PubMed ID: 8240976
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
    Mendoza P, Sánchez C, Contreras HR, Vergara J, Acevedo C, Cabezas J, Huidobro C, Noé G, Castellón EA.
    Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
    [Abstract] [Full Text] [Related]

  • 18. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia.
    Isaacs JT, Coffey DS.
    Endocrinology; 1981 Feb; 108(2):445-53. PubMed ID: 6161001
    [Abstract] [Full Text] [Related]

  • 19. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
    McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E.
    J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
    [Abstract] [Full Text] [Related]

  • 20. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
    Stoner E.
    J Steroid Biochem Mol Biol; 1990 Nov 20; 37(3):375-8. PubMed ID: 1701660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.